Alphabet's Demis Hassabis said AI could cut drug discovery timelines from years to months, with Isomorphic Labs working with Eli Lilly & Novartis on cancer and immune disorders. The DeepMind spinout, built on AlphaFold, raised $600M this year and aims to turn some cancers into chronic diseases. Alphabet shares are up 27% YTD; retail sentiment on Stocktwits remains bearish.